Loralie J. Langman, Ph.D. is a distinguished Researcher at the Mayo Clinic in Rochester, Minnesota, specializing in Laboratory Medicine and Pathology . With a career spanning over 25 years, she has held leadership roles including Chemistry Rotation Director at Mayo School of Graduate Medical Education, Chair of the Clinical Chemistry Exam Committee (American Board of Clinical Chemistry), and President of the Academy of Diagnostics & Laboratory Medicine. Her expertise encompasses clinical chemistry, forensic toxicology, therapeutic drug monitoring , and mass spectrometry , with a focus on transplant medicine, pain management , and pharmacogenomics . PhD in Laboratory Medicine and Pathology (University of Alberta, 1996) Postdoctoral Fellowship in Clinical Chemistry (University of Toronto, 1999) Board certifications in Clinical Chemistry, Forensic Toxicology , and Molecular Diagnostics Her research interests include therapeutic drug monitoring , particularly for immunosuppressive agents and opioids , pharmacogenetic testing in transplant recipients, and mass spectrometry applications in clinical and forensic toxicology. She has led international consensus guidelines on personalized immunosuppressive therapy and oral fluid drug testing . Her recent publications analyze phosphatidylethanol dynamics in transfusion medicine and drug testing in neonatal abstinence syndrome . Scientific honors include the 2025 Canadian Society of Clinical Chemists Outstanding Contribution Award , 2023 Irving Sunshine Award for clinical toxicology, and the 2018 AACC Professor Alvin Dubin Award . She has served on over 40 professional committees, including leadership roles in the International Association of Therapeutic Drug Monitoring and Clinical Toxicology and the College of American Pathologists . Her work bridges clinical diagnostics , forensic science , and transplant pharmacology , with a focus on improving patient care through precise laboratory practices. Currently, Dr. Langman directs Mayo Clinic's clinical chemistry curriculum , co-chairs the Pharmacogenomics Working Group , and contributes to global therapeutic drug monitoring standards. She has advised on guidelines for CLSI and SWGTOX , and her collaborations span institutions in Canada, USA, and Europe .








